Effects of Novel Anti-VEGF Agents with Intravitreal Conbercept in Diabetic Retinopathy: A Systematic Review and Meta-Analysis

Table 1

Study characteristics of included studies.

Author (year)	Study design	No. of participants (male/female)		No. of eyes		Age (years)		Dosage of drug		Follow-up (months)	Baseline BCVA of case		Baseline BCVA of control		Baseline CMT of case		Baseline CMT of control
		IVC	IVTA	IVC	IVTA	IVC	IVTA	IVC	IVTA		Mean	SD	Mean	SD	Mean	SD	Mean	SD
Tao Zhu (2016) [10]	Prospective	32/27	31/28	59	59	42.3 ± 7.2	43.1 ± 6.8	0.1 ml	0.1 ml	3	0.07	0.02	0.07	0.01	643.1	105.9	638.9	102.8
Minglu Li (2015) [11]	Prospective	27/20	26/21	47	47	47.9 ± 2.8	47.3 ± 2.2	0.05 ml	0.1 ml	3	0.06	0.03	0.06	0.01	N.a	N.a	N.a	N.a
Haijing Cao (2016) [12]	Prospective	23/21	24/19	44	43	46.2 ± 6.3	45.5 ± 5.8	0.1 ml	0.1 ml	3	0.06	0.02	0.06	0.01	803.6	129.7	804.2	132.5
Bo Xiao (2017) [13]	Prospective	25/31	27/29	56	56	58.5 ± 4.2	59.1 ± 3.1	0.05 ml	0.05 ml	3	N.a	N.a	N.a	N.a	N.a	N.a	N.a	N.a
Ji Han (2015) [14]	Prospective	20/16	19/17	36	36	46 ± 2.2	45.6 ± 2.3	0.1 ml	0.1 ml	3	0.06	0.01	0.06	0.02	803.4	129.4	804.9	133.8
Hang Shi (2017) [15]	Prospective	20/15	21/14	35	35	45.8 ± 12.1	46.2 ± 12.2	0.1 ml	0.1 ml	6	0.06	0.01	0.07	0.02	N.a	N.a	N.a	N.a
Yantao Jin (2017) [16]	Prospective	21/19	22/18	40	40	65.2 ± 10.3	65.4 ± 10.5	0.1 ml	0.1 ml	N.a	0.06	0.03	0.06	0.02	805.2	132.8	805.4	133
Yong Xiao (2017) [17]	Prospective	27/17	24/19	44	43	50.1 ± 4.9	51.1 ± 5.2	0.1 ml	0.1 ml	3	0.05	0.02	0.06	0.03	806.2	126.6	806.3	132.2
Yiping Li (2017) [18]	Prospective	24/19	26/17	43	43	12.8 ± 4.9	61.3 ± 15.5	0.05 ml	0.1 ml	3	N.a	N.a	N.a	N.a	N.a	N.a	N.a	N.a
Xiaoli Li (2017) [19]	Prospective	30/22	30/22	52	52	50.3 ± 3.2	50.5 ± 3.3	0.1 ml	0.1 ml	3	0.05	0.02	0.05	0.03	804.2	123.5	803.5	125.6
Yunjie Jiang (2017) [20]	Prospective	22/20	24/18	42	42	51.6 ± 11.2	50.8 ± 10.6			3	0.06	0.03	0.06	0.02	803.5	125.7	804.6	128.6
Pengfei Zhang (2018) [21]	Prospective	N.a	N.a	37	37	49.20 ± 3.32	49.12 ± 3.12	0.1 ml	0.1 ml	1	0.07	0.02	0.08	0.01	188.8	40.1	187.8	41.2
Fei Wang (2018) [22]	Prospective	11/8	10/9	19	19	56.4 ± 11.2	55.8 ± 10.1	0.1 ml	0.1 ml	3	N.a	N.a	N.a	N.a	N.a	N.a	N.a	N.a
Na Duan (2018) [23]	Prospective	29/19	32/16	48	48	61.90 ± 8.23	61.76 ± 8.15	0.1 ml	0.1 ml	3	0.06	0.01	0.06	0.02	N.a	N.a	N.a	N.a
Yanjuan Jin (2015) [24]	Prospective	26/23	21/28	49	49	48.3 ± 6.4	47.8 ± 6.9	0.05 ml	0.05 ml	3	0.06	0.01	0.06	0.02	N.a	N.a	N.a	N.a
Linig Wang (2018) [25]	Prospective	31/29	40/20	60	60	65.09 ± 8.12	64.02 ± 9.16	0.05 ml	0.1 ml	1	0.07	0.02	0.08	0.03	692.91	98.23	699.37	97.81
Xueying Ji (2019) [26]	Prospective	33/27	32/28	60	60	45.39 ± 4.22	45.87 ± 5.19	0.05 ml	0.05 ml	6	N.a	N.a	N.a	N.a	514.11	247.43	513.87	218.48
Huili Li (2017) [27]	Prospective	40/36	42/34	76	76	54.43 ± 6.48	54.24 ± 6.33	0.05 ml	0.1 ml	3	0.13	0.09	0.14	0.1	586.42	134.21	587.19	136.32
Xiaoling Zhao (2018) [28]	Prospective	32/28	31/28	60	59	42.6 ± 7.3	43.2 ± 6.7	0.05 ml	0.1 ml	3	0.06	0.01	0.06	0.02	643.5	105.7	638.7	102.6

IVC, intravitreal conbercept; IVTA, intravitreal triamcinolone acetonide; SD, standard deviation; N.a, not applicable; BCVA, best corrected visual acuity; CMT, central macular thickness.